Value of pretreatment automated hemogram as a 5-year survival predictor in uterine cervical cancer clinical stage IIB-IVA

• Autores: Luna-Abanto, Luciana Isabel, Yan-Quiroz, Edgar Fermín
• Formato: artículo
• Fecha de Publicación: 2021
• Institución: Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
• Repositorio: Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
• Lenguaje: español
• OAI Identifier: oai:cmhnaaa_ojs_cmhnaaa.cmhnaaa.org.pe:article/872
• Enlace del recurso: https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/872
• Nivel de acceso: acceso abierto
• Materia: Sobrevida; Neoplasias del Cuello Uterino; Pronósticos; Quimioradioterapia; Survival; Uterine Cervical Neoplasms; Prognostic; Chemoradiotherapy

Objetive: To identify the value of the automated pretreatment blood count as a predictor of actuarial survival and 5-year disease-free actuarial survival in patients with clinical stage IIB-IVA cervical cancer. Material and Methods: Analysis of survival that evaluated 48 patients with pathologic diagnosis of clinical stage IIB-IVA cervical cancer treated with chemoradiotherapy treated at the Medical Oncology service at the Virgen de la Puerta High Complexity Hospital during the period 2015-2017. Results: The mean age of the patients was 51.78 ± 12.06 years (Range: 32-77 years). The average tumor size was 5.55 ± 1.33 cm (Range: 3 - 9 cm). Regarding the clinical stage according to the FIGO classification, it was found that 77.7% was classified as stage IIB, 20.8% as IIIB and 2.1% had a diagnosis of stage IVA cervical cancer. Univariate analysis found that anemia, leukocytosis, thrombocytosis, neutrophil / lymphocyte index, neutrophilia, and high platelet / lymphocyte index are not predictors of 5-year actuarial survival (p> 0.05), in terms of disease-free survival at 5 years it was found that anemia, leukocytosis and pretreatment neutrophil / lymphocyte index showed a trend towards significance (p = 0.05-0.1) and pretreatment neutrophilia is a predictor of 5-year disease-free survival, being statistically significant (0% vs 38.9%, p = 0.026). Conclusion: Pretreatment neutrophilia (> 7,500 μL) is a prognostic factor for 5-year disease-free survival in patients with clinical stage IIB-IVA cervical cancer undergoing chemoradiotherapy